PTO/SB/08a (01-08)
Approved for use through 01/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/594,826
Filing Date	7/17/2007
First Named Inventor	Lazarus et al.
Art Unit	1644
Examiner Name	
Attorney Docket Number	1408/6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,958,241	10-25-2005	Martin et al.	
	2	US-5,130,141	07-14-1992	Law et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	3	WO 2005/094880	10/13/2005	Canadian Blood Services		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-08)
Approved for use through 01/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/594,826
Filing Date	7/17/2007
First Named Inventor	Lazarus et al.
Art Unit	1644
Examiner Name	
Attorney Docket Number	1408/6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	4	Akilesh et al., "The MHC Class I-Like Fc Receptor Promotes Humorally Mediated Autoimmune Disease," Journal of Clinical Investigation, Vol. 113, No. 9, pgs. 1328-1333 (May 2004).	
	5	Binstadt et al, "IgG Fc Receptor Polymorphisms In Human Disease: Implications for Intravenous Immunoglobulin Therapy," J. Allergy Clin. Immunol., Vol. 111, No. 4, pgs. 697-703 (Apr. 2003).	
	6	Bruhns et al., "Colony-Stimulating Factor-1-Dependent Macrophages Are Responsible for IVIG Protection in Antibody-Induced Autoimmune Disease," Immunity, Vol. 18, pgs. 573-581 (April 2003).	
	7	Bussel, J.B., "Fc Receptor Blockade and Immune Thrombocytopenic Purpura," Seminars in Hematology, Vol. 37, No.3, pgs. 261-266. (July 2000). XP008011545.	
	8	Bussell, J.B., "The Use of Intravenous Gamma-Globulin in Idiopathic Thrombocytopenic Purpura, Clinical Immunology and Immunopathology (Nov. 1989) XP002226230, Abstract.	
	9	Cao et al., "The Inositol 3-Phosphatase PTEN Negatively Regulates Fcγ Receptor Signaling, but Supports Toll-Like Receptor 4 Signaling in Murine Peritoneal Macrophages," Journal of Immunology, pgs. 4851-4857 (2004).	
	10	Clynes, Raphael;"Immune Complexes as Therapy for Autoimmunity," Journal of Clinical Investigation, Vol. 115, No. 1, pgs. 25-27 (January 2005).	
	11	Communication pursuant to Article 157(2)(a) EPC corresponding to European Application No. 05732213.3 - 2402 dated October 23, 2007.	
	12	Crow et al., "IVIg Inhibits Reticuloendothelial System Function and Ameliorates Murine Passive-Immune Thrombocytopenia Independent of Anti-Idiotype Reactivity," British Journal of Haematology, Vol. 115, pgs. 679-686 (2001).	
	13	Crow et al., "IVIg-mediated Amelioration of Murine ITP via FcγRIIB Is Independent of SHIP1, SHP-1, and Btk Activity," Blood. Vol. 102, No. 2, pgs. 558 - 560 (July 2003).	
	14	Daëron et al., "Murine Recombinant FcγRIII, but Not FcγRII, Trigger Serotonin Release in Rat Basophilic Leukemia Cells," The Journal of Immunology, Vol. 149, No.4, pgs. 1365-1373, (Aug 1992).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35.U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (01-08)
Approved for use through 01/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/594,826
Filing Date	7/17/2007
First Named Inventor	Lazarus et al.
Art Unit	1644
Examiner Name	
Attorney Docket Number	1408/6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, *etc.*), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	15	De Andres et al., "Phosphoinositide Breakdown Is Associated with Fc-γRII-Mediated Activation of 5'-Lipoxygenase in Murine Eosinophils," Journal of Immunology, Vol. 146, No. 5, pgs. 1566-1570 (March 1, 1991).	
	16	Ericson et al., "Monoclonal Antibody 197 (Anti-FcγRI) Infusion in a Patient with Immune Thrombocytopenia Purpura (ITP) Results in Down-Modulation of FcγRI on Circulating Monocytes, British Journal of Haematology, Vol. 92, pgs. 718-724 (March 1996).	
	17	Latour et al., "Induction of Tumor Necrosis Factor-α Production By Mast Cells Via Fcγr," The Journal of Immunology, Vol. 149, No. 6, pgs. 2155-2162 (September 15, 1992).	
	18	Lazarus et al., "Monoclonal Antibodies Which Mimic the Action of Intravenous Immunoglobulin (mIVIG) Can Inhibit Immune Thrombocytopenia," Biosis (2001) XP002374393, Abstract.	
	19	Nimmerjahn et al., "FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity," Immunity, Vol. 23, pgs. 41 - 51 (July 2005).	
	20	Ott et al., "FcγRIIB as a Potential Molecular Target for Intravenous Gamma Globulin Therapy," J. Allergy Clin. Immunol., Vol. 108, No. 4, pgs. 895-898 (October 2001).	
	21	Pecorino, Lauren, "Stem Cells for Cell-Based Therapies," www.actionbioscience.org/biotech/pecorino2.html (July 2001).	
	22	Reddy, Vijay, "Will Dendritic Cell-Based Therapies Have a Role in Leukemia Therapy?" Invited oral presentation, Shards Cancer Center Symposium, Gainesville, FL. (October 11-12, 2001) http://medinfo.ufl.edu/cme/grounds/cancer/reddylindex.html Parts A and B	
	23	Samuelsson et al., "Anti-Inflammatory Activity of IVIG Mediated through the Inhibitory Fc Receptor," Science, Vol. 291, pgs. 484-486 (2001).	
	24	Siragam et al., "Intravenous Immunoglobulin Ameliorates ITP via Activating Fcγ Receptors on Dendritic Cells," Nature Medicine, Vol. 12, No. 6, pgs. 688-698 (June 2006).	
	25	Takai, Toshiyuki, "Paired Immunoglobulin-Like Receptors and Their MHC Class I Recognition," Immunology, Vol. 115, pgs. 433-440 (2005).	
	26	Timms et al., "Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages," Molecular and Cellular Biology, Vol. 18, No. 7, pgs. 3838-3850 (July 1998).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.